Breaking News
February 19, 2018 - FDA Approves First Blood Test to Detect Concussions
February 19, 2018 - Survival Bump in Bladder Cancer with Keytruda
February 18, 2018 - Scientists describe the mechanism of heart regeneration in the zebrafish
February 18, 2018 - Scientists uncover the structure of microtubule motor proteins
February 18, 2018 - Light-activated cancer drugs without toxic side effects are closer to becoming reality
February 18, 2018 - Pioneering research could provide novel insight into how genomic information is read
February 18, 2018 - Pearls From: David Putrino, PhD
February 18, 2018 - Researchers uncover how cancer stem cells drive triple-negative breast cancer
February 18, 2018 - Morning Break: Anti-Anti-Vaxxers; Private Piercings Prohibited; A Case for Pelvic Massage
February 18, 2018 - Lower-dose radiation effective, safe for HPV+ head and neck cancer after induction chemo
February 18, 2018 - Specialist residential service for adults with autism opens in Swansea
February 18, 2018 - FDA Moves to Limit Loperamide Doses per Package
February 18, 2018 - Alcohol use disorder – Genetics Home Reference
February 18, 2018 - Autism might be better detected using new two-minute questionnaire
February 18, 2018 - Hand hygiene-intervention practices may reduce risk of infection among nursing home patients
February 18, 2018 - Researchers develop most sophisticated mini-livers to date
February 18, 2018 - Obamacare Helped More Young Women Get Prenatal Care: Study
February 18, 2018 - School-Based Program Fails to Dent Kids’ Obesity
February 18, 2018 - Research compares neural activity in children with and without autism spectrum disorder
February 18, 2018 - Poor fitness levels increase the risk dementia, concludes study
February 18, 2018 - Risk Score May Reveal if Kids are Victims of Ill-Treatment
February 18, 2018 - Adding Folic Acid to Corn Masa Flour May Prevent Birth Defects
February 18, 2018 - Acute treatment suppresses posttraumatic arthritis in ankle injury
February 18, 2018 - A Role for Budesonide in Autoimmune Hepatitis?
February 18, 2018 - Lupus patients exhibit altered cell proteins, a discovery with potential implications for diagnostics
February 18, 2018 - Muscle plays vital role in regulating heat loss from the hands
February 18, 2018 - High-tech brain scans can provide new way to define intelligence
February 18, 2018 - Study reveals the association between ultra-processed foods and cancer
February 18, 2018 - Prescription Opioid Use Tied to Higher Pneumonia Risk
February 18, 2018 - A non-invasive method to detect Alzheimer’s disease
February 18, 2018 - Deletion of specific enzyme leads to improvement in memory and cognitive functions
February 18, 2018 - Amyloid protein may be transmitted through neurosurgical instruments, study suggests
February 18, 2018 - Electric brain signals of males and females show differences
February 18, 2018 - American Heart Association commends McDonald’s for offering healthier menu in kids’ meals
February 18, 2018 - Parents Find Kids’ Weight Report Cards Hard to Swallow
February 18, 2018 - Does a Financial Conflict of Interest Ever Expire?
February 18, 2018 - Exercise can improve Alzheimer’s symptoms
February 18, 2018 - Scientists develop green chemistry method to improve pharmaceutical manufacturing efficiency
February 17, 2018 - ‘A Time Clock to a Tissue Clock’ for Acute Stroke Care
February 17, 2018 - Cancer Care Gets Personal | NIH News in Health
February 17, 2018 - Do more youth use or do youth use more?
February 17, 2018 - Eating faster linked to obesity
February 17, 2018 - Who’s Still Smoking? ACS Report Highlights Most Vulnerable Adults
February 17, 2018 - Study of smoking and genetics illuminates complexities of blood pressure
February 17, 2018 - Study reveals new link between bone cells and blood glucose level
February 17, 2018 - Children with reading challenges may have lower than expected binocular vision test results
February 17, 2018 - Mass Shootings Trigger Change for Emergency Medicine
February 17, 2018 - ECMO helps revive woman thought to be drowned
February 17, 2018 - Learning stress-reducing techniques may benefit people with epilepsy
February 17, 2018 - Shedding Pounds Before Weight-Loss Surgery a Smart Move
February 17, 2018 - FDA Approves New Cystic Fibrosis Drug Combo
February 17, 2018 - Augmented Reality helps surgeons to ‘see through’ tissue and reconnect blood vessels
February 17, 2018 - Emotional state affects operation of the entire brain instead of being restricted to specific regions
February 17, 2018 - Apalutamide Slows Metastasis in Prostate Cancer
February 17, 2018 - Kids’ well visits linked to lower appendicitis complications
February 17, 2018 - New NK cell-based immunotherapy effective against several types of leukemia
February 17, 2018 - Producing Super-Swelled Lyotropic Crystals for Drug Development
February 17, 2018 - Pfizer Receives Breakthrough Therapy Designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis
February 17, 2018 - Molecular Imaging Flags Risk of AAA Rupture
February 17, 2018 - Researchers identify risk factors for sleep apnea during pregnancy
February 17, 2018 - More work required to find the right drug dosage for pediatric patients
February 17, 2018 - Factors ID’d That Predict RA Remission with Etanercept
February 17, 2018 - A handout or a hand up? How we judge others guides how we help others
February 17, 2018 - ACR receives grant to focus on projects that reduce health disparities
February 17, 2018 - Pimavanserin Might Be Safer Alternative to Ease Dementia Psychosis
February 17, 2018 - Risks of Lung Screening Seen Outweighing Benefits in Many with Smoking History
February 17, 2018 - The impact of Hurricane Harvey on pregnant moms
February 17, 2018 - Gene editing tool used to detect cancer
February 17, 2018 - Researchers detail molecular atlas of cells that form brain’s blood vessels
February 17, 2018 - TUM scientists observe formation of myelin sheaths around nerve fibers
February 17, 2018 - Worst Flu Season Yet? | Medpage Today
February 17, 2018 - Finding the root cause of bronchiolitis symptoms
February 17, 2018 - Climbing stairs reduces hypertension and strengthens muscles
February 17, 2018 - Nature paper unveils bacterial division
February 16, 2018 - Postoperative pain control following extensive pelvic exenteration
February 16, 2018 - Daré Bioscience, Inc. Enters into License and Collaboration Agreement for a Product with the Potential to Receive the First FDA Approval for Female Sexual Arousal Disorder
February 16, 2018 - Havana Embassy Staff: ‘Concussion Without Concussion’?
February 16, 2018 - Family impact of congenital Zika syndrome likely to last a lifetime
February 16, 2018 - STI Prevention Helped By Also Discussing Pot, Alcohol Use
February 16, 2018 - New method maps the dopamine system in Parkinson’s patients
New drugs Erenumab and Fremanezumab show promise for migraine

New drugs Erenumab and Fremanezumab show promise for migraine

image_pdfDownload PDFimage_print

Migraine headaches affect thousands of Americans and millions worldwide. There are several medications that are being prescribed for migraines and for many these do not work well.

In a couple of latest studies, two new drugs for migraine headaches have come up to prove their effectiveness in reducing the severity of the condition in persons who have not responded to traditional therapies. The two drugs are Erenumab and Fremanezumab.

Image Credit: FotoDuets / Shutterstock

Image Credit: FotoDuets / Shutterstock

The studies are both published this week in the New England Journal of Medicine.

Erenumab is one of the anti-migraine drugs that is developed jointly by Novartis and Amgen. They tried the drugs in 955 individuals who suffered from migraines. Fremanezumab, developed by Teva Pharmaceuticals, was similarly tried in 1,130 people. Both drugs showed effectiveness in reducing the frequency and severity of the migraine headaches in nearly 50 percent of the individuals and the manufacturers have submitted the papers and data for approval to the Food and Drug Administration.

The first study with Erenumab was a 6-month study where 40 percent of the participants were given a low-dose monthly injection of the test drug Erenumab. Half of the patients received a high-dose monthly injection of Erenumab. The rest of the participants were given a placebo injection. Those who received the Erenumab injection reported that the frequency and severity of their migraine headaches were reduced by half.

A quarter of patients who received placebo injection also reported a reduction in symptoms. The study reports that the frequency of migraines was around eight days per month before medication for the participants. Those on low dose Erenumab had a reduction of 3.2 days of migraine on average. Those on high dose had a migraine days reduction of 3.7 days while those on placebo had a 1.8 days reduction in the migraine days per month.

In the second study Fremanezumab was given both as a monthly injection and a quarterly injection to the patients. It was compared to placebo. After the drug was administered, 41 percent of those who received the monthly injection showed a reduction of symptoms by half. Only 18 percent of those who received placebo showed a similar reduction in symptoms. Among participants who received an injection every three months, 38 percent showed a half reduction of symptoms. Checking upon migraine headache days, from an average of 13 days a month in all participants, the reduction was 4 to 5 days in those who received fremanezumab injection. The number of days reduced was 2.5 days only with placebo injection.

Both these drugs are produced in the laboratory and act by mimicking the body’s immune cells. Thus, they are called monoclonal antibodies. These agents can bind to a protein within the body called calcitonin gene-related peptide (CGRP). CGRP is released when a person experiences a migraine pain. Blocking this protein could help reduce the severity and frequency of migrains speculate researchers.

Dr. Peter Goadsby, professor of Neurology at University College London and co-author of the erenumab study explained that these drugs are not useful in all individuals. But they may be helpful in persons who have failed to respond to other traditional anti-migraine medications. These could be targeting the migraine trigger he said and that is a novel mechanism of action.

Erenumab would be in the markets to prevent episodic attacks of migraine in individuals who have less than 15 attacks a month. Fremanezumab would be used in persons who have chronic migraines with 15 or more attacks a month. There are two more similar drugs that are being developed by rival companies and these two might be on the shelves by next year speculate the manufacturers.

Source:

A Controlled Trial of Erenumab for Episodic Migraine — NEJM

Tagged with:

About author

Related Articles